The effect of combination therapy of Donepezil and Memary for moderate to severe Alzheimer's disease
Phase 4
- Conditions
- moderate to severe Alzheimer's disease
- Registration Number
- JPRN-UMIN000005883
- Lead Sponsor
- YASUJI YAMAMOTO
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with contraindication for donepezil or/and memantine. Patients who is judged as inappropriate for entry to this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We will carry out tree contents of SIB, FAST and MMSE for 3 times at every 12 week-point during 24 weeks from the start-point of medication and evaluate the results of usefulness.
- Secondary Outcome Measures
Name Time Method We will carry out two contents of NPI-D and ADCS-ADL for 3 times at every 12 week-point during 24 weeks from the start-point of medication and evaluate the results of usefulness.